NKT-cell glycolipid agonist as adjuvant in synthetic vaccine

作者：Liu, Zheng^*; Guo, Jun^*

来源：Carbohydrate Research, 2017, 452: 78-90.

DOI：10.1016/j.carres.2017.10.006

• Adjuvant
• NKT cell
• alpha-galactosylceramide
• CD1d
• Conjugation

NKT cells are CD1d-restricted, glycolipid antigen-reactive, immunoregulatory T lymphocytes that can serve as a bridge between the innate and adaptive immunities. NKT cells have a wide range of therapeutic application in autoimmunity, transplant biology, infectious disease, cancer, and vaccinology. Rather than triggering "danger signal" and eliciting an innate immune response, alpha GalCer-based NKT-cell agonist act via a unique mechanism, recruiting NKT cells which play a T helper-like role even without peptide as Th epitope. Importantly, the non-polymorphism of CD1d render glycolipid a universal helper epitope, offering the potential to simplify the vaccine construct capable of eliciting consistent immune response in different individuals. This review details recent advances in the design of synthetic vaccines using NKT-cell agonist as adjuvant, highlighting the role of organic synthesis and conjugation technique to enhance the immunological actives and to simplify the vaccine constructs.

• 出版日期2017-11-27
• 单位华中师范大学